Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | 30M | 35M | 43M | 38M | 40M |
| Gross Profit | 20M | 24M | 32M | 13M | 26M |
| Operating Income | -8M | 6M | 11M | -25M | 3M |
| EBITDA | -6M | 6M | 11M | -26M | 3M |
| Net Income | -12M | 2M | 6M | -33M | 1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.239
+14.35% today
1Y Change
-91.88%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synergy CHC Corp. (SNYR) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.24 and down 91.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -12.8%, EPS growth of -553.6%, a dividend yield of 0.0%. What stands out right now is revenue -12.8%, EPS -553.6%, free cash flow +46.2% with operating margin -5.9% and ROIC -48.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNYR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNYR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNYR Max Drawdown
-95.29%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNYR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$40.2M
+4.7% YoY
FY Net Income
$1.4M
+104.3% YoY
Free Cash Flow
-$1.6M
+81.2% YoY
Revenue Growth
-12.8%
EPS Growth
-553.6%
Gross Margin
66.7%
Net Margin
-40.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | 30M | 35M | 43M | 38M | 40M |
| Gross Profit | 20M | 24M | 32M | 13M | 26M |
| Operating Income | -8M | 6M | 11M | -25M | 3M |
| EBITDA | -6M | 6M | 11M | -26M | 3M |
| Net Income | -12M | 2M | 6M | -33M | 1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 688K | 633K | 2M | 2M |
| Total Assets | 10M | 16M | 12M | 19M | 13M |
| Total Liabilities | 25M | 33M | 40M | 52M | 16M |
| Shareholder Equity | -15M | -17M | -27M | -34M | -4M |
| Total Debt | 27M | 28M | 28M | 23M | 9M |
| Net Debt | 24M | 27M | 27M | 21M | 7M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+81.2% YoY
Capital Expenditures
2
-100.0% YoY
Free Cash Flow
2M
+81.2% YoY
Key ratios
Gross Margin
66.7%
Operating Margin
-5.9%
Net Margin
-40.6%
ROE
83.1%
Debt / Equity
-1.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.